| Autor: |
Trimpert J; Institut für Virologie, Freie Universität Berlin, Berlin, Germany., Adler JM; Institut für Virologie, Freie Universität Berlin, Berlin, Germany.; Department of Infectious Diseases and Respiratory Medicine, Charité, Universitätsmedizin Berlin, Berlin, Germany., Eschke K; Institut für Virologie, Freie Universität Berlin, Berlin, Germany., Abdelgawad A; Institut für Virologie, Freie Universität Berlin, Berlin, Germany., Firsching TC; Institut für Tierpathologie, Freie Universität Berlin, Berlin, Germany., Ebert N; Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., Thao TTN; Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.; Graduate School for Biomedical Science, University of Bern, Bern, Switzerland., Gruber AD; Institut für Tierpathologie, Freie Universität Berlin, Berlin, Germany., Thiel V; Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., Osterrieder N; Institut für Virologie, Freie Universität Berlin, Berlin, Germany.; Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon, Hong Kong., Kunec D; Institut für Virologie, Freie Universität Berlin, Berlin, Germany. |
| Abstrakt: |
Vaccines are instrumental and indispensable in the fight against the COVID-19 pandemic. Several recent SARS-CoV-2 variants are more transmissible and evade infection- or vaccine-induced protection. We constructed live attenuated vaccine candidates by large-scale recoding of the SARS-CoV-2 genome and showed that the lead candidate, designated sCPD9, protects Syrian hamsters from a challenge with ancestral virus. Here, we assessed immunogenicity and protective efficacy of sCPD9 in the Roborovski dwarf hamster, a nontransgenic rodent species that is highly susceptible to SARS-CoV-2 and severe COVID-19–like disease. We show that a single intranasal vaccination with sCPD9 elicited strong cross-neutralizing antibody responses against four current SARS-CoV-2 variants of concern, B.1.1.7 (Alpha), B.1.351 (Beta), B.1.1.28.1 (Gamma), and B.1.617.2 (Delta). The sCPD9 vaccine offered complete protection from COVID-19–like disease caused by the ancestral SARS-CoV-2 variant B.1 and the two variants of concern B.1.1.7 and B.1.351. |
